Efficacy of various drugs in the prevention of posterior capsule opacification: experimental study of rabbit eyes.
OBJECTIVE
To assess the efficacy of various drugs in the prevention of posterior capsule opacification (PCO) in a closed capsular bag technique.


METHODS
Ophthalmic Biophysics Center, Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida, USA.


METHODS
Lens material was removed using phacoaspiration or phacoemulsification through a microcapsulorhexis according to the hardness of the crystalline lens correlated with the weight and age of the rabbits. A mixture of an ophthalmic viscosurgical device (sodium hyaluronate 1.4% [SHA]) and a drug was injected into the empty capsular bag, allowed to remain inside for 3 minutes, and removed. The capsular bag was rinsed with balanced salt solution (BSS) and refilled with SHA. In a group of rabbits, the capsulorhexis was sealed with a minicapsulorhexis valve (MCV). Rabbits were treated with 1 of the following: SHA (control), BSS, mitomycin-C (MMC, 0.2 mg/mL), ethylenediaminetetraacetic acid (EDTA) (10 mM and 15 mM), 5-fluorouracil (5-FU, 33 mg/mL), acetic acid (3%, 0.3%, and 0.003%), and distilled water.


RESULTS
Upon completion of the study, the control and treated eyes had PCO and new lens material (not residual). Anterior capsule proliferation was observed in eyes treated with 5-FU. The order of PCO appearance (earliest to latest) was as follows: 15 mM EDTA, SHA, MMC, acetic acid 0.3%, acetic acid 3%, BSS, distilled water (small animals; no MCV), acetic acid 0.003%, 5-FU, 10 mM EDTA, and distilled water (large animals; MCV). The earliest appearance was day 1 postoperatively and the latest, day 47.


CONCLUSIONS
Distilled water and 10 mM EDTA treatments were the most efficient in retarding the appearance of PCO.
Fernandez
Viviana
V
Ophthalmic Biophysics Center, Bascom Palmer Eye Institute, Miami, Florida, USA.
Fragoso
Miryam A
MA
Billotte
Christian
C
Lamar
Peggy
P
Orozco
Marcia A
MA
Dubovy
Sander
S
Willcox
Mark
M
Parel
Jean-Marie
JM
D000085:Acetates / Q000494:pharmacology; D019342:Acetic Acid / Q000494:pharmacology; D000818:Animals; D019923:Capsulorhexis; D002386:Cataract / Q000473:pathology / Q000517:prevention & control*; D049109:Cell Proliferation / Q000187:drug effects*; D004338:Drug Combinations; D004492:Edetic Acid / Q000494:pharmacology; D004847:Epithelial Cells / Q000187:drug effects*; D005260:Female; D005472:Fluorouracil / Q000494:pharmacology; D006821:Hyaluronoglucosaminidase / Q000494:pharmacology; D007903:Lens Capsule, Crystalline / Q000187:drug effects* / Q000473:pathology; D008903:Minerals / Q000494:pharmacology; D016685:Mitomycin / Q000494:pharmacology; D009883:Ophthalmic Solutions / Q000494:pharmacology*; D018918:Phacoemulsification; D011183:Postoperative Complications / Q000517:prevention & control*; D011817:Rabbits; D012965:Sodium Chloride / Q000494:pharmacology
D000085:Acetates; C030660:BSS solution; D004338:Drug Combinations; D008903:Minerals; D009883:Ophthalmic Solutions; D012965:Sodium Chloride; D016685:Mitomycin; D004492:Edetic Acid; D006821:Hyaluronoglucosaminidase; D019342:Acetic Acid; D005472:Fluorouracil